A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia
Not yet recruitingOBSERVATIONAL
Enrollment
500
Participants
Timeline
Start Date
April 20, 2024
Primary Completion Date
July 1, 2026
Study Completion Date
July 1, 2026
Conditions
Cancer, Therapy-Related
Interventions
DRUG
Herombopag Olamine Tablets
Herombopag Olamine；combined rhTPO;combined IL-11
All Listed Sponsors
lead
Hebei Medical University Fourth Hospital
OTHER
NCT06376435 - A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia | Biotech Hunter | Biotech Hunter